Capacity demands for biologic-based drugs are shifting due to high-volume demands for blockbuster and biosimilar drugs, and smaller-volume demands of targeted therapies. How is the industry responding to production-related challenges?
Pharmaceutical Technology and BioPharm InternatioOriginal Article
